These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36592498)

  • 1. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
    Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
    Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
    Williams RM; Kareff SA; Sackstein P; Roy T; Luta G; Kim C; Taylor KL; Tammemägi MC
    Lung Cancer; 2022 Jul; 169():55-60. PubMed ID: 35644087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
    JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
    Toumazis I; Cao P; de Nijs K; Bastani M; Munshi V; Hemmati M; Ten Haaf K; Jeon J; Tammemägi M; Gazelle GS; Feuer EJ; Kong CY; Meza R; de Koning HJ; Plevritis SK; Han SS
    Ann Intern Med; 2023 Mar; 176(3):320-332. PubMed ID: 36745885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    J Thorac Oncol; 2020 Nov; 15(11):1738-1747. PubMed ID: 32822843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.
    Williams RM; Li T; Luta G; Wang MQ; Adams-Campbell L; Meza R; Tammemägi MC; Taylor KL
    Cancer; 2022 May; 128(9):1812-1819. PubMed ID: 35201610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
    Walter J; Kauffmann-Guerrero D; Muley T; Reck M; Fuge J; Günther A; Majeed RW; Savai R; Koch I; Dinkel J; Schneider C; Senghas K; Kobinger S; Manapov F; Thomas M; Kahnert K; Winter H; Behr J; Tammemägi M; Tufman A
    Cancer Med; 2023 Apr; 12(7):8880-8896. PubMed ID: 36707972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
    Hüsing A; Kaaks R
    Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    Smeltzer MP; Liao W; Faris NR; Fehnel C; Goss J; Shepherd CJ; Ramos R; Qureshi T; Mukhopadhyay A; Ray MA; Osarogiagbon RU
    J Thorac Oncol; 2023 Feb; 18(2):158-168. PubMed ID: 36208717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
    JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
    JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria-Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    JTO Clin Res Rep; 2021 Mar; 2(3):100137. PubMed ID: 34590000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
    Tomonaga Y; de Nijs K; Bucher HC; de Koning H; Ten Haaf K
    Int J Cancer; 2024 Feb; 154(4):636-647. PubMed ID: 37792671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
    Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.